Browsing Tag
BioNTech
24 posts
US medical groups fill CDC policy gap with independent 2026-27 respiratory vaccine recommendations
Major US medical groups issue independent flu, COVID-19 and RSV vaccine guidance as the traditional CDC recommendation process remains unsettled.
Tempus AI company profile: How diagnostics, health data and AI are building a precision medicine platform
Tempus AI, Inc. has built a precision medicine business around genomic diagnostics, multimodal health data, artificial intelligence and pharmaceutical research services. Ambry Genetics, Deep 6 AI, Paige and OneOme have widened that platform, while the proposed Personalis acquisition could bring molecular residual disease technology, laboratory economics and longitudinal cancer monitoring more tightly inside the company.
Moderna faces fresh mRNA patent assault from CureVac as BioNTech tightens legal grip on COVID-19 vaccine royalties
Moderna just settled $950 million in mRNA litigation. Now BioNTech-owned CureVac wants Spikevax royalties too. The patent war is widening.
Baroness Blackwood to lead Health Data Research Service as UK fast-tracks NHS data access for medical innovation
Baroness Nicola Blackwood will lead the UK’s new Health Data Research Service, fast-tracking NHS data access for lifesaving research. Read the full update.
How the UK’s £55bn R&D funding plan aims to transform health, AI, and clean energy sectors
UK confirms £55B R&D funding through 2030 to power innovation in AI, health, and clean energy. Find out how this public investment could reshape UK industry.
The in-vivo revolution: How pharma is racing to reprogram immunity inside the body
Explore how pharma giants like Bristol Myers Squibb are driving the in-vivo revolution to reprogram immunity and transform autoimmune and cancer care.
Can Bristol Myers Squibb’s $1.5bn Orbital deal make in-vivo CAR-T the next big breakthrough in autoimmune care?
Bristol Myers Squibb’s $1.5 B Orbital buyout bets on in-vivo CAR-T and RNA delivery to reshape autoimmune care. Find out what it means for BMY investors.
Can seasonal COVID‑19 shots follow the flu vaccine playbook—and will Americans comply in 2025?
Will Americans embrace annual COVID-19 shots like flu vaccines? Explore how LP.8.1, FDA guidance, and public trust shape the 2025 rollout.
Pfizer and BioNTech secure FDA approval for LP.8.1-adapted COMIRNATY vaccine for high-risk groups
Pfizer and BioNTech's LP.8.1-adapted COVID-19 vaccine gets FDA approval for high-risk groups. Find out what this means for the 2025–2026 rollout season.
Syncona’s Autolus and BioNTech forge alliance to propel CAR-T therapies
Syncona Ltd, a prominent investor in the life sciences sector, has announced a significant strategic collaboration through its…